CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.

Francesco SchettiniMichela PalleschiFrancesca MannozziFara Brasó-MaristanyLorenzo CecconettoPatricia GalvánMarita MariottiAlessia FerrariEmanuela ScarpiAnna MiserocchiOriana NanniEsther SanfeliuAleix PratAndrea RoccaUgo De Giorgi

Published in: The oncologist (2024)

The KENDO trial, although closed prematurely, adds further evidence supporting CDK4/6i + ET use in aggressive HR+/HER2-negative MBC instead of chemotherapy. PAM50 IS, genomic, and immunological features are promising biomarkers to personalize therapeutic choices.

Keyphrases

phase iii
open label
phase ii
cell cycle
placebo controlled
locally advanced
double blind
clinical trial
study protocol
copy number
squamous cell carcinoma
chemotherapy induced
rectal cancer
cell proliferation
gene expression